What are PARP inhibitors and who should take them

PARP Inhibitors: Educational Overview

What Are PARP Inhibitors?

PARP inhibitors are a class of targeted cancer drugs that work by blocking an enzyme called PARP (poly-ADP-ribose polymerase). Here's how they function:

The Basic Mechanism: Your cells naturally repair DNA damage through different pathways. PARP is one repair system. Cancer cells with certain genetic mutations (particularly in BRCA1/BRCA2 genes) rely heavily on PARP to survive. When PARP inhibitors block this repair pathway, cancer cells can't fix their DNA damage and die, while normal cells are often less affected.

Think of it like removing a backup exit from a building—cancer cells with specific genetic vulnerabilities become trapped, while other cells have alternative routes.

Who Typically Takes PARP Inhibitors?

According to NCCN Guidelines and ASCO recommendations, PARP inhibitors are primarily used for patients with:

1. BRCA1/BRCA2 Mutations

• These genetic mutations significantly impair DNA repair, making cancer cells particularly vulnerable to PARP inhibition
• Used across multiple cancer types: ovarian, breast, pancreatic, and prostate cancers

2. Homologous Recombination Deficiency (HRD)

• Some patients without BRCA mutations still have defective DNA repair pathways
• Testing can identify this vulnerability, expanding who may benefit

3. Specific Cancer Types & Situations:

• Ovarian cancer: Often first-line maintenance therapy for advanced disease
• Breast cancer: Particularly HER2-negative, BRCA-mutated breast cancers
• Pancreatic cancer: BRCA-mutated pancreatic cancers
• Prostate cancer: Metastatic castration-resistant prostate cancer with HRD

FDA-Approved PARP Inhibitors

Several options exist, including olaparib, rucaparib, niraparib, and talazoparib—each with specific approvals for different cancer types and situations.

Important Questions for Your Oncologist

If PARP inhibitors are being considered for you:

1. "Have I been tested for BRCA mutations or HRD status? If not, should I be?"
2. "Is a PARP inhibitor appropriate for my specific cancer type and stage?"
3. "Which PARP inhibitor would you recommend, and why?"
4. "What are the potential side effects, and how would we manage them?"
5. "How long would I take this medication, and how do we monitor if it's working?"

Key Takeaway

PARP inhibitors represent precision medicine—they're most effective when there's a specific genetic vulnerability present. Your oncologist will determine whether genetic testing is appropriate for you and whether a PARP inhibitor fits your treatment plan based on your complete medical picture, cancer type, stage, and test results.

---

Sources Referenced:

• NCCN Guidelines for relevant cancer types
• ASCO Clinical Practice Guidelines
• FDA drug approvals and indications

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.